In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study

被引:60
|
作者
Hawser, Stephen P. [1 ]
Bouchillon, Samuel K. [2 ]
Hoban, Daryl J. [2 ]
Badal, Robert E. [2 ]
机构
[1] IHMA Europe Sarl, CH-1066 Epalinges, Switzerland
[2] Int Hlth Management Associates Inc, Schaumburg, IL USA
关键词
Ertapenem; Intra-abdominal infections; SMART; ESBL; ANTIMICROBIAL RESISTANCE TRENDS; SPECTRUM BETA-LACTAMASES;
D O I
10.1016/j.ijantimicag.2009.07.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing multiyear surveillance study to monitor worldwide antimicrobial resistance trends among aerobic and facultative anaerobic Gram-negative bacilli (GNB) isolated from intra-abdominal infections. During 2005-2007, a total of 255 laboratories from 37 countries in five global regions collected intra-abdominal GNB for antimicrobial susceptibility testing using broth microdilution according to Clinical and Laboratory Standards Institute guidelines. A total of 19 703 GNB were isolated from intra-abdominal infections, comprising 5476, 6633 and 7594 GNB were isolated in the years 2005, 2006 and 2007 from 75, 84 and 96 medical centres, respectively. The most frequently isolated organisms were Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae, of which 18.0% of E. coli and 26.2% of K. pneumoniae were positive for extended-spectrum beta-lactamase (ESBL). Overall, resistance among GNB increased during 2005-2007 and resistance rates in 2007 were generally higher than data from previous years. Ertapenem and imipenem were the only agents that maintained consistent activity against GNB, including most ESBL-producing isolates. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:585 / 588
页数:4
相关论文
共 50 条
  • [31] Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets
    Mendes, Rodrigo E.
    Castanheira, Mariana
    Woosley, Leah N.
    Stone, Gregory G.
    Bradford, Patricia A.
    Flamm, Robert K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (06)
  • [32] Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections
    Tickler, Isabella A.
    Kawa, Diane
    Obradovich, Anne E.
    Fang, Ferric C.
    Tenover, Fred C.
    ANTIBIOTICS-BASEL, 2023, 12 (09):
  • [33] Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017)
    Beirao, Elisa Maria
    Rodrigues, Suellen da Silva
    de Andrade, Tarik Klain
    Serra, Fernando Brandao
    Negra de Paula, Marina Della
    Bueno Polis, Thales Jose
    Gales, Ana Cristina
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2020, 24 (04) : 310 - 321
  • [34] Epidemiologic Trends, Occurrence of Extended-Spectrum β-Lactamase Production, and Performance of Ertapenem and Comparators in Patients with Intra-Abdominal Infections: Analysis of Global Trend Data from 2002-2007 from the SMART Study
    Hawser, Stephen P.
    Bouchillon, Samuel K.
    Hoban, Daryl J.
    Badal, Robert E.
    SURGICAL INFECTIONS, 2010, 11 (04) : 371 - 378
  • [35] In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017
    Karlowsky, James A.
    Lob, Sibylle H.
    Young, Katherine
    Motyl, Mary R.
    Sahm, Daniel F.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (03) : 274 - 281
  • [36] Trending Eight Years of In Vitro Activity of Ertapenem and Comparators against Escherichia coli from Intra-abdominal Infections in North America-SMART 2002-2009
    Hawser, S. P.
    Badal, R. E.
    Bouchillon, S. K.
    Hoban, D. J.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (05) : 266 - 272
  • [37] Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009-2011
    Bouchillon, Sam K.
    Badal, Robert E.
    Hoban, Daryl J.
    Hawser, Stephen P.
    CLINICAL THERAPEUTICS, 2013, 35 (06) : 872 - 877
  • [38] A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) 2007-2016
    Zhang, Jiangang
    Zhao, Chunjiang
    Chen, Hongbin
    Li, Henan
    Wang, Qi
    Wang, Zhanwei
    Zhang, Feifei
    Wang, Hui
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 2311 - 2319
  • [39] Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
    James A. Karlowsky
    Sibylle H. Lob
    Katherine Young
    Mary R. Motyl
    Daniel F. Sahm
    BMC Microbiology, 21
  • [40] Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011-2020
    Yan, Mengyao
    Zheng, Bo
    Li, Yun
    Lv, Yuan
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 2325 - 2337